健脾化积方治疗中晚期胃癌化疗患者临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.2

基金项目:


Clinical Study on Jianpi Huaji Prescription for Patients with Advanced Gastric Cancer Undergoing Chemotherapy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨健脾化积方治疗中晚期胃癌化疗患者的临床疗效。方法:将76例中晚期胃癌患者按随机数字表法分为对照组和研究组各38例。研究组予健脾化积方联合标准化疗方案,并予化疗相关的辅助治疗;对照组予标准化疗方案及化疗相关的辅助治疗。2个化疗周期后观察2组患者瘤体大小、肿瘤标志物、体质量指数、临床症状、生活质量的变化情况。结果:研究组总有效率为83.33%,高于对照组44.12%,差异有统计学意义(P<0.05)。治疗前,2 组血清癌胚抗原(CEA)、CA125、CA199、CA724 水平比较,差异无统计学意义(P>0.05)。治疗后,研究组CEA、CA125、CA199、CA724 水平较治疗前降低(P<0.05),对照组CEA、CA125、CA199水平较治疗前降低(P<0.05)。治疗前,2组体质量指数(BMI) 比较,差异无统计学意义(P>0.05)。治疗后,研究组BMI值较治疗前升高,且高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组生活质量评定量表(QOL) 评分较治疗前升高,且研究组QOL评分高于对照组,差异均有统计学意义(P<0.05)。结论:健脾化积方可有效改善中晚期胃癌化疗患者的临床症状,提高患者生活质量,且临床应用安全可靠,可作为中晚期胃癌化疗患者的辅助用药。

    Abstract:

    Abstract: Objective: To investigate the clinical effect of Jianpi Huaji prescription for patients with advanced gastric cancer undergoing chemotherapy. Methods:A total of 76 cases of patients with advanced gastric cancer were divided into the control group and the study group according to the random number table method,38 cases in each group. The control group was given standard chemotherapy regimen and chemotherapy- related adjuvant therapy, and the study group was additionally treated with Jianpi Huaji prescription based on the treatment of the control group. After two cycles of chemotherapy,the changes in the size of tumor,tumor markers,body mass index,clinical symptoms and quality of life in the two groups were observed. Results:The total effective rate was 83.33% in the study group,higher than that of 44.12% in the control group,the difference being significant(P<0.05). Before treatment,there was no significant difference being found in the comparison of the levels of carcinoembryonic antigen(CEA),CA125,CA199 and CA724 between the two groups (P>0.05). After treatment, the levels of CEA, CA125, CA199 and CA724 in the study group were decreased when compared with those before treatment(P<0.05), and the levels of CEA, CA125 and CA199 in the control group were decreased when compared with those before treatment(P<0.05). Before treatment, there was no significant difference being found in the comparison of the values of body mass index(BMI) between the two groups(P>0.05). After treatment,the value of BMI in the study group was increased when compared with that before treatment and it was higher than that in the control group, differences being significant(P<0.05). After treatment, the scores of Quality of Life Scale(QOL) in the two groups were increased when compared with those before treatment,and the above score in the study group was higher than that in the control group,differences being significant(P<0.05). Conclusion:Jianpi Huaji prescription can effectively improve the clinical symptoms and quality of life of patients with advanced gastric cancer undergoing chemotherapy,which has safe and reliable clinical application and can be used as their adjuvant medicines.

    参考文献
    相似文献
    引证文献
引用本文

杨忠,赵欣,李秀荣.健脾化积方治疗中晚期胃癌化疗患者临床研究[J].新中医,2020,52(11):94-97

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-06-04
  • 出版日期: